What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Breast cancer
His main research concerns Breast cancer, Internal medicine, Oncology, Genome-wide association study and Cancer.
His Breast cancer study combines topics from a wide range of disciplines, such as Single-nucleotide polymorphism, Gynecology and Bioinformatics.
His Internal medicine research incorporates elements of Germline mutation and Pathology.
His Oncology study integrates concerns from other disciplines, such as Odds ratio, Case-control study, Bevacizumab, Prospective cohort study and Triple-negative breast cancer.
His Genome-wide association study study incorporates themes from Estrogen receptor and Genetic predisposition.
His studies in Cancer integrate themes in fields like Chromatin, microRNA and Estrogen.
His most cited work include:
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy (491 citations)
- RAD51B in Familial Breast Cancer (399 citations)
- RAD51B in Familial Breast Cancer (399 citations)
What are the main themes of his work throughout his whole career to date?
Peter A. Fasching spends much of his time researching Breast cancer, Internal medicine, Oncology, Cancer and Chemotherapy.
Peter A. Fasching combines subjects such as Genome-wide association study and Single-nucleotide polymorphism with his study of Breast cancer.
To a larger extent, Peter A. Fasching studies Genetics with the aim of understanding Genome-wide association study.
His study in Odds ratio, Hazard ratio, Trastuzumab, Epirubicin and Clinical trial falls under the purview of Internal medicine.
His Oncology research is multidisciplinary, incorporating elements of Circulating tumor cell, Prospective cohort study, Pathology, Docetaxel and Triple-negative breast cancer.
The various areas that he examines in his Metastatic breast cancer study include Progression-free survival and Clinical significance.
He most often published in these fields:
- Breast cancer (72.17%)
- Internal medicine (64.03%)
- Oncology (55.66%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (64.03%)
- Breast cancer (72.17%)
- Oncology (55.66%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Breast cancer, Oncology, Cancer and Metastatic breast cancer.
His study in the fields of Chemotherapy, Trastuzumab and Randomized controlled trial under the domain of Internal medicine overlaps with other disciplines such as In patient.
His Breast cancer research integrates issues from Odds ratio and Clinical trial.
His study in Oncology is interdisciplinary in nature, drawing from both Fulvestrant, Hazard ratio, Pertuzumab, Epirubicin and Triple-negative breast cancer.
The concepts of his Cancer study are interwoven with issues in Tolerability and Family medicine.
His Metastatic breast cancer research is multidisciplinary, incorporating perspectives in Interim analysis, Lapatinib and Clinical significance.
Between 2019 and 2021, his most popular works were:
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. (126 citations)
- Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. (8 citations)
- Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. (8 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
Peter A. Fasching mainly focuses on Breast cancer, Internal medicine, Oncology, Triple-negative breast cancer and Cancer.
The Breast cancer study combines topics in areas such as Odds ratio and Epidemiology.
His is doing research in Randomized controlled trial, Chemotherapy, Clinical trial, Tissue microarray and Adverse effect, both of which are found in Internal medicine.
His studies deal with areas such as Chemotherapy regimen and Hazard ratio as well as Randomized controlled trial.
His Chemotherapy research includes themes of Adjuvant and Abemaciclib.
His Oncology study combines topics in areas such as Epirubicin, Fulvestrant and Immunotherapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
